Wed, Jul 30, 2014, 6:14 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

InterMune, Inc. Message Board

  • duragen duragen Jan 22, 2009 12:23 PM Flag

    ITMN has good management

    When ITMN announced their data for ITMN-191, they properly announced a conference call a day before to notify their investor's important data is coming and the data was releaded at 7:00am eastern. Now lets look at bad management, AspenBio comes out with a pr release at 9:15am to announce very important data for their appendicitis diagnostic test, it failed, stock down 85 percent, they did not have a conference call to investor's until the next morning. I expect when ITMN is ready to release pirfenidone data, good or bad, you will see a pr release a day early about a conference call time. Should be anyday now.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It is now going on three months since last patient visit. I honestly can't remember any trial that took three months to report top line results. One of two things is going on here. They are either totally incomptent, or are data mining the failed trials looking for some positives. Neither scenario is a good one.

    • Dan Welch has been as good as his track record in big pharma - he's been around the launch of some big products (Plavix etc). I'm much more impressed with the other execs now that Blatt has moved on - lots of UCSF connections suggests that they are probably decent physician-scientists.

      Several of the board members represent major debtholders and shareholders, so you figure they must have an investor's interest in the outcome of the R & D program.

45.72+0.15(+0.33%)Jul 30 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.